Longitudinal data provides insight as to how patients cycle through medications and as to the factors influencing providers' treatment decisions.
Survival analyses are performed that look at treatment persistency and reasons for medication switching and discontinuation.
Examination of disease activity and lack of response to therapies can identify the burden of illness and unmet need of autoimmune patient populations.
Prescribing practices are examined including whether providers are following a treat-to-target treatment paradigm.
Understanding the patient's experience is pursued through the evaluation of patient reported outcomes.
Treatment effectiveness and comparative effectiveness by drug, between classes of drugs and within classes of drugs using validated outcome measures.
Analyses identify subgroups of patients who will have better responses to a particular drug class as compared to competitors.
CorEvitas' PHI enables linking deep clinical data with other sources such as Medicare, National Death Index and other dataset such as claims and labs at an individual level.
CorEvitas has linked its clinical data sets with Medicare data, creating an even more robust data set for analysis. Such data includes claims which permits cost-effectiveness and other health care utilization analyses.
CorEvitas has worked closely with the National Death Index to link data sets to gain further clarity on the patient journey. Such data is utilized to validate CorEvitas data and provides a complete set of data on individuals who no longer participate in the registry.
CorEvitas is able to link its data with other sources including EMRs and labs. CorEvitas protects patient confidentiality while matching patient data on an individual basis using data tokenization.